Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Interleukin-15 receptor (IL-15R) agonists show promise for inducing anti-tumor immunity but face clinical development challenges due to dose-limiting toxicities.
• Understanding the complete IL-15R signaling mechanism is crucial for overcoming these limitations.

Purpose of the Study:

• To identify the molecular mechanisms that restrain IL-15R signaling in natural killer (NK) cells.
• To uncover novel drug targets for enhancing IL-15R-based immunotherapies.

Main Methods:

• Genome-wide CRISPR screens were employed to systematically identify genes regulating IL-15R signaling.
• Functional assays were used to validate the roles of key identified enzymes in IL-15R degradation and NK cell activity.
• In vivo studies in mouse models assessed the anti-tumor efficacy of targeting identified pathways.

Main Results:

• Ubiquitin-dependent degradation was revealed as the dominant mechanism limiting IL-15R signaling.
• UBE2F and ARIH2 were identified as critical enzymes involved in IL-15RB degradation via the Cullin-5 RING E3 ligase (CRL5) complex.
• Ablation of ARIH2 or UBE2F enhanced IL-15R signaling, leading to increased NK cell cytotoxicity and superior in vivo anti-tumor immunity.

Conclusions:

• The study identifies UBE2F and ARIH2 as key regulators of IL-15R signaling and potential drug targets.
• Inhibiting these enzymes can enhance NK cell-mediated anti-tumor immunity, offering a promising strategy for cancer immunotherapy.